Cladribine
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Cladribine
- Pharmacist Assessment Report
- Cladribine: From Hairy Cell Leukemia to Parameningeal Embryonal Rhabdomyosarcoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cladribine: From Hairy Cell Leukemia to Parameningeal Embryonal Rhabdomyosarcoma
One-Sentence Summary
Cladribine is a purine nucleoside analog originally used for hairy cell leukemia (including its variant) and relapsing-remitting multiple sclerosis. The TxGNN model predicts it may be effective for parameningeal embryonal rhabdomyosarcoma, but no clinical trials and no directly relevant publications currently support this prediction. It is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hairy cell leukemia, hairy cell leukemia variant, relapsing-remitting multiple sclerosis (from the knowledge graph; the India license text has no indication recorded) |
| Predicted New Indication | Parameningeal embryonal rhabdomyosarcoma |
| TxGNN Prediction Score | 0.9977 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, cladribine is a purine nucleoside analog. It is cytotoxic to lymphocytes through activation by deoxycytidine kinase, which disrupts DNA synthesis. Its efficacy in hairy cell leukemia, a lymphoid malignancy, is established.
The link to rhabdomyosarcoma is weak. Rhabdomyosarcoma is a solid tumor of soft tissue, and no mechanistic rationale for a lymphocyte-directed purine analog in this setting is documented. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The same pattern appears in the other top predictions: prostate, vaginal (botryoid), and bile duct embryonal subtypes, the parent term “rhabdomyosarcoma”, and liver sarcoma. These all score between 0.9970 and 0.9977 and probably share one similarity-driven signal. Any further work would need preclinical validation first.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the lead predicted indication.
For the seventh-ranked prediction (liver sarcoma), one paper was retrieved: 15241520 (2004, case report, Der Hautarzt). It describes successful cladribine therapy in smoldering systemic mastocytosis, a hematologic neoplasm. It is most likely a retrieval mismatch and does not support liver sarcoma or rhabdomyosarcoma.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 37767 | Cladrim 10mg Injection (Fresenius Kabi India Pvt Ltd) | Vial of 1 injection | Not recorded in the available data |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (purine nucleoside analog / antimetabolite) |
| Myelosuppression Risk | High. The knowledge graph lists neutropenia, thrombocytopenia, agranulocytosis and anemia among its contraindicated conditions. |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count with differential, liver and renal function; neurological assessment given the peripheral neuropathy signal |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Contraindicated conditions (not label text): kidney disease, pyoureter, thrombocytopenia, neutropenia, agranulocytosis, anemia (including macrocytic anemia), peripheral nervous system disease, peripheral neuropathy, hyperuricemia.
- Drug Interactions: 344 interactions were found. Major interactions include:
- Corticosteroids: hydrocortisone, triamcinolone (including ophthalmic), dexamethasone, betamethasone, budesonide, prednisolone, prednisone
- Deferiprone
- Radiopharmaceuticals and radioimmunotherapies: ibritumomab tiuxetan, iobenguane (I-131), tositumomab (with and without I-131), samarium (153Sm) lexidronam, strontium chloride Sr-89
Moderate interactions include palifermin, dipyridamole, cilostazol and eltrombopag.
Package insert warnings and contraindications for the India product were not available. Please refer to the package insert for label safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score (L5), with no clinical trials and no relevant literature. There is no demonstrated mechanistic link between cladribine and rhabdomyosarcoma, and the drug carries substantial myelosuppression and neurotoxicity concerns.
To proceed, the following is needed:
- Preclinical evidence (cell-line or xenograft data) of cladribine activity in rhabdomyosarcoma models
- Detailed mechanism of action data, to assess whether deoxycytidine kinase-dependent activity is relevant in this tumor type
- India package insert warnings and contraindications, which are required before any safety screening
- Confirmation of the approved indication text for the India license
- A systematic literature search targeted at rhabdomyosarcoma and nucleoside analogs, since the one retrieved paper is off-target
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.